
Medpace Holdings (MEDP) Stock Forecast & Price Target
Medpace Holdings (MEDP) Analyst Ratings
Bulls say
Medpace Holdings is projected to experience approximately 21% bookings growth in 2025, reflecting a shift towards more consistent revenue growth, bolstered by strong RFP volume and improved win rates. Despite a reduction in 2024 sales guidance, the company has raised its EBITDA outlook and EPS targets, indicating improved financial performance metrics with adjusted EBITDA significantly outperforming expectations. Operational efficiencies related to hiring and technology are anticipated to support margins, reinforcing a robust business environment conducive to revenue acceleration.
Bears say
Medpace Holdings has demonstrated a concerning trend following a significant bookings miss in the second quarter, with revenue falling short of expectations at $533 million compared to an estimate of $542 million. The company reported net new business awards of $534 million, which was well below the anticipated $596 million, resulting in a disappointing net book-to-bill ratio of 1.00 times for the quarter. Furthermore, ongoing constraints in biotech funding may lead to elevated cancellation rates, prompting a reduction in revenue forecasts for both 2024 and 2025 by $32 million and $135 million, respectively.
This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.
Medpace Holdings (MEDP) Analyst Forecast & Price Prediction
Start investing in Medpace Holdings (MEDP)
Order type
Buy in
Order amount
Est. shares
0 shares